Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

Objective. To assess the efficacy of rituximab (RTX) in SSc. Methods. Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Daoussis, Dimitrios, Liossis, Stamatis-Nick C., Tsamandas, Athanassios C., Kalogeropoulou, Christina, Kazantzi, Alexandra, Sirinian, Chaido, Karampetsou, Maria, Yiannopoulos, Georgios, Andonopoulos, Andrew P.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806066/
https://www.ncbi.nlm.nih.gov/pubmed/19447770
http://dx.doi.org/10.1093/rheumatology/kep093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806066/
https://www.ncbi.nlm.nih.gov/pubmed/19447770
http://dx.doi.org/10.1093/rheumatology/kep093

Ejemplares similares